Morgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap

cnbc2021-05-28

Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

phantom74
2021-05-31
phantom74
Like and comments
daniao
2021-05-28
daniao
Like and comment please 🥺
- Liha:
  Done
ycTeo
2021-05-28
ycTeo
Ok
angskk
2021-05-28
angskk
Ok comment and like pls
- Cucumbers:
  Okay
ChrisCen
2021-05-28
ChrisCen
Like n comment plz
- geraldino:
  ok
SP1980
2021-05-28
SP1980
Hi
- Liha:
  Ho

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1115119024?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-05-28 19:00","share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","id":"1115119024","market":"us","top_or_hot":-1,"title":"Morgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap","media":"cnbc","content":"<div>\n<p>Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html\">网页链接</a>\n\n</div>\n","source":"cnbc_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-28 19:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JNJ","symbol_name":"强生","start_time":0,"source_url":"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html","article_id":"1115119024","we_media_id":null,"thumbnails":[],"rights":{"source":"cnbc_highlight","url":"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.ArticleHeader-headline{#titleStyle#}a{#lv2TextColor#}.ArticleHeader-time, .Author-authorNameAndSocial a{#sourceStyle#;}","selectors":".PageBuilder-pageWrapper","filters":".ArticleHeader-eyebrow, .RelatedTags-relatedTags","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=1115119024","pubTimestamp":1622199653,"columns":[],"sourceInfo":{"source_id":"cnbc_highlight","name":"CNBC"},"weMediaInfo":null,"summary":"Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, a","collect":0,"end_time":0,"defaultTopTitle":"cnbc.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"JNJ":"强生"},"translate_title":"摩根士丹利给了强生一个跑赢大盘评级，说股票看起来很便宜","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":0.9},"content_text":"Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development of a Covid-19 vaccine, but the stock hasn’t been a big winner. Shares have risen just under 15% over the past year.Analyst David Risinger assumed coverage of the stock with an overweight rating, saying in a note to clients on Friday that strength in multiple business units should help shares rise.“We are Overweight JNJ shares based upon strong growth prospects, diversification across three distinct business segments – Pharmaceuticals, Medical Devices & Diagnostics, and Consumer – and an attractive valuation relative to the S&P,” the note said.The stock is trading at 16-times 2022 estimated earnings compared to 20-times for the S&P 500, according to Morgan Stanley.One area that should show particularly strong results in the near term is medical devices & diagnostics, which was hampered last year by restrictions on non-Covid care in hospitals across the country.“Underlying improvement should become more visible as COVID headwinds abate. We model 17.7% YoY growth in 2021 vs 2020, driven by procedure recovery and new product ramps,” the note said about the business line.Morgan Stanley set a price target of $187 per share for Johnson & Johnson, which is nearly 11% above where the stock closed on Thursday.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":110007357,"gmtCreate":1622415061079,"gmtModify":1634101806715,"author":{"id":"3570342809089528","authorId":"3570342809089528","name":"phantom74","avatar":"https://static.tigerbbs.com/c87ef2af41b8696be86cceafb5b5723d","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3570342809089528","authorIdStr":"3570342809089528"},"htmlText":"Like and comments","listText":"Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/110007357","repostId":1115119024,"repostType":4,"repost":{"id":"1115119024","kind":"news","pubTimestamp":1622199653,"share":"https://www.laohu8.com/m/news/1115119024?lang=&edition=full","pubTime":"2021-05-28 19:00","market":"us","language":"en","title":"Morgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap","url":"https://stock-news.laohu8.com/highlight/detail?id=1115119024","media":"cnbc","summary":"Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, a","content":"<div>\n<p>Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-28 19:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1115119024","content_text":"Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development of a Covid-19 vaccine, but the stock hasn’t been a big winner. Shares have risen just under 15% over the past year.Analyst David Risinger assumed coverage of the stock with an overweight rating, saying in a note to clients on Friday that strength in multiple business units should help shares rise.“We are Overweight JNJ shares based upon strong growth prospects, diversification across three distinct business segments – Pharmaceuticals, Medical Devices & Diagnostics, and Consumer – and an attractive valuation relative to the S&P,” the note said.The stock is trading at 16-times 2022 estimated earnings compared to 20-times for the S&P 500, according to Morgan Stanley.One area that should show particularly strong results in the near term is medical devices & diagnostics, which was hampered last year by restrictions on non-Covid care in hospitals across the country.“Underlying improvement should become more visible as COVID headwinds abate. We model 17.7% YoY growth in 2021 vs 2020, driven by procedure recovery and new product ramps,” the note said about the business line.Morgan Stanley set a price target of $187 per share for Johnson & Johnson, which is nearly 11% above where the stock closed on Thursday.","news_type":1,"symbols_score_info":{"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":134942566,"gmtCreate":1622204076455,"gmtModify":1634182893299,"author":{"id":"3575541782223727","authorId":"3575541782223727","name":"daniao","avatar":"https://static.tigerbbs.com/f1193bc7847be1da820c2d94723471b2","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3575541782223727","authorIdStr":"3575541782223727"},"htmlText":"Like and comment please 🥺","listText":"Like and comment please 🥺","text":"Like and comment please 🥺","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/134942566","repostId":1115119024,"repostType":4,"repost":{"id":"1115119024","kind":"news","pubTimestamp":1622199653,"share":"https://www.laohu8.com/m/news/1115119024?lang=&edition=full","pubTime":"2021-05-28 19:00","market":"us","language":"en","title":"Morgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap","url":"https://stock-news.laohu8.com/highlight/detail?id=1115119024","media":"cnbc","summary":"Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, a","content":"<div>\n<p>Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-28 19:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1115119024","content_text":"Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development of a Covid-19 vaccine, but the stock hasn’t been a big winner. Shares have risen just under 15% over the past year.Analyst David Risinger assumed coverage of the stock with an overweight rating, saying in a note to clients on Friday that strength in multiple business units should help shares rise.“We are Overweight JNJ shares based upon strong growth prospects, diversification across three distinct business segments – Pharmaceuticals, Medical Devices & Diagnostics, and Consumer – and an attractive valuation relative to the S&P,” the note said.The stock is trading at 16-times 2022 estimated earnings compared to 20-times for the S&P 500, according to Morgan Stanley.One area that should show particularly strong results in the near term is medical devices & diagnostics, which was hampered last year by restrictions on non-Covid care in hospitals across the country.“Underlying improvement should become more visible as COVID headwinds abate. We model 17.7% YoY growth in 2021 vs 2020, driven by procedure recovery and new product ramps,” the note said about the business line.Morgan Stanley set a price target of $187 per share for Johnson & Johnson, which is nearly 11% above where the stock closed on Thursday.","news_type":1,"symbols_score_info":{"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4486404,"gmtCreate":1622212047761,"gmtModify":1635396306658,"authorId":3580021038510346,"author":{"id":3580021038510346,"idStr":"3580021038510346","authorId":3580021038510346,"name":"Liha","avatar":"https://static.tigerbbs.com/a4ba484754a4e8fc7a7c54ab52161218","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":134942566,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"EN"},{"id":134929164,"gmtCreate":1622201915458,"gmtModify":1634182910301,"author":{"id":"3579157368166900","authorId":"3579157368166900","name":"ycTeo","avatar":"https://static.tigerbbs.com/df0e9f8b3d852acdba5ee0e19ad18cd7","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3579157368166900","authorIdStr":"3579157368166900"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/134929164","repostId":1115119024,"repostType":4,"repost":{"id":"1115119024","kind":"news","pubTimestamp":1622199653,"share":"https://www.laohu8.com/m/news/1115119024?lang=&edition=full","pubTime":"2021-05-28 19:00","market":"us","language":"en","title":"Morgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap","url":"https://stock-news.laohu8.com/highlight/detail?id=1115119024","media":"cnbc","summary":"Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, a","content":"<div>\n<p>Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-28 19:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1115119024","content_text":"Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development of a Covid-19 vaccine, but the stock hasn’t been a big winner. Shares have risen just under 15% over the past year.Analyst David Risinger assumed coverage of the stock with an overweight rating, saying in a note to clients on Friday that strength in multiple business units should help shares rise.“We are Overweight JNJ shares based upon strong growth prospects, diversification across three distinct business segments – Pharmaceuticals, Medical Devices & Diagnostics, and Consumer – and an attractive valuation relative to the S&P,” the note said.The stock is trading at 16-times 2022 estimated earnings compared to 20-times for the S&P 500, according to Morgan Stanley.One area that should show particularly strong results in the near term is medical devices & diagnostics, which was hampered last year by restrictions on non-Covid care in hospitals across the country.“Underlying improvement should become more visible as COVID headwinds abate. We model 17.7% YoY growth in 2021 vs 2020, driven by procedure recovery and new product ramps,” the note said about the business line.Morgan Stanley set a price target of $187 per share for Johnson & Johnson, which is nearly 11% above where the stock closed on Thursday.","news_type":1,"symbols_score_info":{"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":134962437,"gmtCreate":1622201560129,"gmtModify":1634182913535,"author":{"id":"3575447019432232","authorId":"3575447019432232","name":"angskk","avatar":"https://static.tigerbbs.com/14993a1ab2e959534763e33dc2415981","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3575447019432232","authorIdStr":"3575447019432232"},"htmlText":"Ok comment and like pls","listText":"Ok comment and like pls","text":"Ok comment and like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/134962437","repostId":1115119024,"repostType":4,"repost":{"id":"1115119024","kind":"news","pubTimestamp":1622199653,"share":"https://www.laohu8.com/m/news/1115119024?lang=&edition=full","pubTime":"2021-05-28 19:00","market":"us","language":"en","title":"Morgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap","url":"https://stock-news.laohu8.com/highlight/detail?id=1115119024","media":"cnbc","summary":"Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, a","content":"<div>\n<p>Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-28 19:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1115119024","content_text":"Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development of a Covid-19 vaccine, but the stock hasn’t been a big winner. Shares have risen just under 15% over the past year.Analyst David Risinger assumed coverage of the stock with an overweight rating, saying in a note to clients on Friday that strength in multiple business units should help shares rise.“We are Overweight JNJ shares based upon strong growth prospects, diversification across three distinct business segments – Pharmaceuticals, Medical Devices & Diagnostics, and Consumer – and an attractive valuation relative to the S&P,” the note said.The stock is trading at 16-times 2022 estimated earnings compared to 20-times for the S&P 500, according to Morgan Stanley.One area that should show particularly strong results in the near term is medical devices & diagnostics, which was hampered last year by restrictions on non-Covid care in hospitals across the country.“Underlying improvement should become more visible as COVID headwinds abate. We model 17.7% YoY growth in 2021 vs 2020, driven by procedure recovery and new product ramps,” the note said about the business line.Morgan Stanley set a price target of $187 per share for Johnson & Johnson, which is nearly 11% above where the stock closed on Thursday.","news_type":1,"symbols_score_info":{"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4484380,"gmtCreate":1622201638402,"gmtModify":1635396462863,"authorId":3576794201858255,"author":{"id":3576794201858255,"idStr":"3576794201858255","authorId":3576794201858255,"name":"Cucumbers","avatar":"https://static.tigerbbs.com/e738e1e68e462d14f96cf6ac301fbd37","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":134962437,"type":1,"supId":0,"prevId":0,"content":"Okay","text":"Okay","html":"Okay"}],"langContent":"EN"},{"id":134968326,"gmtCreate":1622201348065,"gmtModify":1634182915186,"author":{"id":"3573646272982241","authorId":"3573646272982241","name":"ChrisCen","avatar":"https://static.tigerbbs.com/9ed69e076449c1e1af50807f0353afc3","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3573646272982241","authorIdStr":"3573646272982241"},"htmlText":"Like n comment plz","listText":"Like n comment plz","text":"Like n comment plz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/134968326","repostId":1115119024,"repostType":4,"repost":{"id":"1115119024","kind":"news","pubTimestamp":1622199653,"share":"https://www.laohu8.com/m/news/1115119024?lang=&edition=full","pubTime":"2021-05-28 19:00","market":"us","language":"en","title":"Morgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap","url":"https://stock-news.laohu8.com/highlight/detail?id=1115119024","media":"cnbc","summary":"Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, a","content":"<div>\n<p>Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-28 19:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1115119024","content_text":"Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development of a Covid-19 vaccine, but the stock hasn’t been a big winner. Shares have risen just under 15% over the past year.Analyst David Risinger assumed coverage of the stock with an overweight rating, saying in a note to clients on Friday that strength in multiple business units should help shares rise.“We are Overweight JNJ shares based upon strong growth prospects, diversification across three distinct business segments – Pharmaceuticals, Medical Devices & Diagnostics, and Consumer – and an attractive valuation relative to the S&P,” the note said.The stock is trading at 16-times 2022 estimated earnings compared to 20-times for the S&P 500, according to Morgan Stanley.One area that should show particularly strong results in the near term is medical devices & diagnostics, which was hampered last year by restrictions on non-Covid care in hospitals across the country.“Underlying improvement should become more visible as COVID headwinds abate. We model 17.7% YoY growth in 2021 vs 2020, driven by procedure recovery and new product ramps,” the note said about the business line.Morgan Stanley set a price target of $187 per share for Johnson & Johnson, which is nearly 11% above where the stock closed on Thursday.","news_type":1,"symbols_score_info":{"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4484339,"gmtCreate":1622201360526,"gmtModify":1635396465058,"authorId":3578990110970495,"author":{"id":3578990110970495,"idStr":"3578990110970495","authorId":3578990110970495,"name":"geraldino","avatar":"https://static.tigerbbs.com/32f151d5c2b15c07d43c4d7f9f49fbab","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":134968326,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":134984246,"gmtCreate":1622200829985,"gmtModify":1634182918921,"author":{"id":"3573379860144244","authorId":"3573379860144244","name":"SP1980","avatar":"https://static.tigerbbs.com/101a00da82e124351de89d6d885f76b9","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3573379860144244","authorIdStr":"3573379860144244"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/134984246","repostId":1115119024,"repostType":4,"repost":{"id":"1115119024","kind":"news","pubTimestamp":1622199653,"share":"https://www.laohu8.com/m/news/1115119024?lang=&edition=full","pubTime":"2021-05-28 19:00","market":"us","language":"en","title":"Morgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap","url":"https://stock-news.laohu8.com/highlight/detail?id=1115119024","media":"cnbc","summary":"Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, a","content":"<div>\n<p>Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley gives Johnson & Johnson an overweight rating, says stock looks cheap\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-28 19:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.cnbc.com/2021/05/28/johnson-and-johnson-stock-jnj-overweight-morgan-stanley.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1115119024","content_text":"Investors should bet onJohnson & Johnsonfor its diversified growth and relatively cheap valuation, according to Morgan Stanley.The company has been in focus over the past year due to its development of a Covid-19 vaccine, but the stock hasn’t been a big winner. Shares have risen just under 15% over the past year.Analyst David Risinger assumed coverage of the stock with an overweight rating, saying in a note to clients on Friday that strength in multiple business units should help shares rise.“We are Overweight JNJ shares based upon strong growth prospects, diversification across three distinct business segments – Pharmaceuticals, Medical Devices & Diagnostics, and Consumer – and an attractive valuation relative to the S&P,” the note said.The stock is trading at 16-times 2022 estimated earnings compared to 20-times for the S&P 500, according to Morgan Stanley.One area that should show particularly strong results in the near term is medical devices & diagnostics, which was hampered last year by restrictions on non-Covid care in hospitals across the country.“Underlying improvement should become more visible as COVID headwinds abate. We model 17.7% YoY growth in 2021 vs 2020, driven by procedure recovery and new product ramps,” the note said about the business line.Morgan Stanley set a price target of $187 per share for Johnson & Johnson, which is nearly 11% above where the stock closed on Thursday.","news_type":1,"symbols_score_info":{"JNJ":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4486411,"gmtCreate":1622212064145,"gmtModify":1635396306329,"authorId":3580021038510346,"author":{"id":3580021038510346,"idStr":"3580021038510346","authorId":3580021038510346,"name":"Liha","avatar":"https://static.tigerbbs.com/a4ba484754a4e8fc7a7c54ab52161218","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":134984246,"type":1,"supId":0,"prevId":0,"content":"Ho","text":"Ho","html":"Ho"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":17,"commentSize":12,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.9","shortVersion":"4.34.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115119024","isCrawlerRequest":true}